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INHIBITION OF HUMAN TELOMERASE BY 
A G-QUADRUPLEX-INTERACTION 
COMPOUND 
The present application is a division of copending U.S. 
application Ser. No. 09/730,893, filed Dec. 5, 2000, which is 
a division of U.S. application Ser. No. 09/244,675, filed Feb. 
4, 1999, and now issued as U.S. Pat. No. 6,156,763, which 
claims the priority of U.S. Provisional Patent Application 
Serial No. 60/073,629, filed Feb. 4, 1998. The entire dis 
closure of each of these applications is incorporated herein 
by reference without disclaimer. 
The government may own rights in the present invention 
pursuant to contract number U19CA-67760-02, and contract 
number NCDDG, CA67760 from the National Cancer 
Institute, and contract number CA49751 and contract num 
ber CA77000 from the National Institutes of Health. 
BACKGROUND OF THE INVENTION 
I. Field of the Invention 
This invention relates to the field of cancer therapy. The 
invention also relates to Screening methods for identifying 
pharmacologically active compounds that may be useful for 
treating proliferative diseases. More particularly, the inven 
tors have identified non-nucleoside molecule compounds 
that interact with specific DNA structures and which inhibit 
human telomerase. 
II. Description of Related Art 
Cancer, which is a cell proliferative disorder, is one of the 
leading causes of disease, being responsible for 526,000 
deaths in the United States each year (Boring et al., 1993). 
For example, breast cancer is the most common form of 
malignant disease among women in Western countries and, 
in the United States, is the most common cause of death 
among women between 40 and 55 years of age (Forrest, 
1990). The incidence of breast cancer is increasing, espe 
cially in older women, but the cause of this increase is 
unknown. Malignant melanoma is another form of cancer 
whose incidence is increasing at a frightening rate, at least 
sixfold in the United States since 1945, and is the single 
most deadly of all skin diseases (Fitzpatrick, 1986). 
One of the devastating aspects of cancer is the propensity 
of cells from malignant neoplasms which disseminate from 
their primary Site to distant organs and develop into meta 
static cancers. Animal tests indicate that about 0.01% of 
circulating cancer cells from Solid tumors establish Success 
ful metastatic colonies (Fidler, 1993). Despite advances in 
Surgical treatment of primary neoplasms and aggressive 
therapies, most cancer patients die as a result of metastatic 
disease. Hence, there is a need for new and more efficacious 
cures for cancer. 
The ends of chromosomes have specialized Sequences, 
termed telomeres, comprising tandem repeats of Simple 
DNA sequences. Human telomeres consist of the Sequence 
5'-TTAGGG (SEQ ID No. 1) (Blackburn, 1991; Blackburn 
et al., 1995). Telomeres have several functions apart from 
protecting the ends of chromosomes, the most important of 
which appear to be associated with Senescence, replication, 
and the cell cycle clock (Counter et al., 1992). Progressive 
rounds of cell division result in a shortening of the telomeres 
by some 50-200 nucleotides per round. Almost all tumor 
cells have shortened telomeres, which are maintained at a 
constant length (Allshire et al., 1988; Harley et al., 1990; 
Harley et al., 1994) and are associated with chromosome 
instability and cell immortalization. 
The enzyme telomerase adds the telomeric repeat 












of telomere length in tumor cells commensurate with Suc 
cessive rounds of cell division. Telomerase is a DNA poly 
merase with an endogenous RNA template (Feng et al., 
1995), on which the nascent telomeric repeats are synthe 
sized. A significant recent finding has been that approxi 
mately 85-90% of all human cancers are positive for 
telomerase, both in cultured tumor cells and primary tumor 
tissue, whereas most Somatic cells appear to lack detectable 
levels of telomerase (Kim et al., 1994; Hiyama et al., 1995a). 
This finding has been extended to a wide range of human 
tumors (see, for example, references Broccoli, 1994 and 
Hiyama et al., 1995b) and is likely to be of use in diagnosis. 
Human telomerase has been proposed as a novel and 
potentially highly Selective target for antitumor drug design 
(Feng et al., 1995; Rhyu et al., 1995; Parkinson, 1996). 
Studies with antisense constructs against telomerase RNA in 
HeLa cells show that telomere shortening is produced, 
together with the death of these otherwise immortal cells 
(Feng et al., 1995). Sequence-specific peptide-nucleic acids 
directed against telomerase RNA have also been found to 
exert an inhibitory effect on the enzyme Norton et al., 1996). 
Among chemical agents, 2,6-diamido-anthraquinones 
have been reported as DNA-interactive agents (Collier and 
Neidle, 1988; 1992; Agbandje et al., 1992). These com 
pounds have been shown to act as selective DNA triplex 
interactive compounds (Fox et al., 1995; Haq et al., 1996), 
with reduced affinity for duplex DNA and only moderate 
conventional cytotoxicity in a range of tumor cell lines. A 
carbocyanine dye, 3,3'-diethyloxadicarbocyanine (DODC), 
has been reported to bind dimeric hairpin G-quadruplex 
structures (Chen et al., 1996). 
This invention describes a novel class of non-nucleoside 
molecules that are telomerase inhibitors. These compounds 
have demonstrated their ability to interact with telomeres 
which form Structures called the G-quadruplex Structures. 
AS telomeres are involved in controlling the cell cycle, cell 
replication and aging, these inhibitors of telomerase prevent 
uncontrolled cell growth and the immortality of tumor cells. 
SUMMARY OF THE INVENTION 
The present invention has demonstrated for the first time 
that a non-nucleoside, Small molecule can target the 
G-quadruplex Structure and can act as a telomerase inhibitor. 
Accordingly, methods have been developed that identify 
these classes of compounds and Several inhibitors identified. 
Compounds Such as those described here, which interact 
Selectively with G-quadruplex Structures and inhibit 
telomerase, are expected to be useful as inhibitors of the 
proliferation of cells that require telomerase to maintain 
telomere length for continued growth. The invention thus 
relates to novel methods for identifying compounds that will 
be useful in this regard, and also includes new classes of 
telomerase inhibitors. In this regard, Several perylene com 
pounds and carbocyanines have been shown to interact with 
G-quadruplex Structures. Since telomerase appears to be 
found almost exclusively in tumor cells, these agents are 
contemplated to be useful as antitumor agents. 
In one aspect of the invention, compounds that act as 
telomerase inhibitors have been identified. It has been found 
that compounds that bind to the human G-quadruplex Struc 
ture inhibit the human telomerase. The identification of Such 
G-quadruplex interactive agents is an efficient approach for 
identifying human telomerase inhibitors. Methods for iden 
tifying these G-quadruplex interactive agents include iden 
tifying compounds whose three-dimensional Structure is 
complementary to that of the G-quadruplex Structure. 
US 6,623,930 B2 
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Another method for identifying G-quadruplex interactive 
compounds is to identify compounds that interact with 
G-quadruplexes using Such methods as dye displacement or 
melting points of G-quadrupleX/compound hybrids. 
More particularly, candidate compounds that inhibit 
telomerase activity are identified by first obtaining the 
three-dimensional Structure of a compound that might inter 
act with the G-quadrupleX.Selected compound. The comple 
mentarity of the compound to human telomere DNA 
G-quadruplex is then determined. If there is a high degree of 
complementarity, telomerase inhibition activity is indicated. 
Alternatively, one can contact a telomerase inhibitor can 
didate compound with human DNA G-quadruplex; and then 
determine the melting point of the human DNA 
G-quadruplex. The inventors have found that an increase in 
melting point of the quadrupleX indicates telomerase inhibi 
tory activity of the compound. 
Additionally, telomerase inhibitors may be identified by 
first preparing a DNAG-quadruplex/dye complex with a dye 
intercalated into the G-quadruplex; then contacting complex 
with a telomerase inhibitor candidate. Displacement of the 
dye in the complex identifies the candidate as a telomerase 
inhibitor. 
Yet another aspect of this invention is to provide non 
nucleoside inhibitors of telomerase. Using the disclosed 
Screening methods, compounds have been identified that 
bind to human G-quadruplex Structures. The invention 
includes perylene compounds, exemplified by N,N'-bis(2- 
dimethylaminoethyl)-3,4,9,10-perylenetetracarboxylic acid 
diimide that are useful telomerase inhibitors. Novel com 
pounds such as N,N'-bis(2-piperdinoethyl)-3,4,9,10 
perylenetetracarboxylic acid diimide are also within the 
Scope of the invention. 
A preferred G-quadruplex Structure is formed from the 
sequence d(AGGGTTAGGGTTAGGGTTAGGG) (SEQ ID 
No. 2) or the sequences d(TTAGGG) (SEQ ID No. 1), 
d(TAAGGGT), (SEQ ID No. 3), or d(TTAGGGTT) (SEQ 
ID No. 4) either alone or in the presence of a G-quadruplex 
interactive perylene diimide of general Structure I. The 
structures were determined by NMR spectroscopy. 
Alternatively, one may determine the three-dimensional 
Structure of potential G-quadrupleX interactive agents by 
X-ray diffraction or molecular mechanics calculations. Pre 
ferred programs for determining the degree of complemen 
tarity between the potential G-quadrupleX interactive agent 
and these G-quadruplex structures include DOCK, 
autoDOCK, AMBER and SYBYL. The preferred methods 
for generating orientations between the potential 
G-quadruplex interactive agents and these G-quadruplex 
structures are manual and using the DOCK or autoDOCK 
programs. The cutoff for determining the likelihood that the 
orientation of the potential G-quadrupleX interactive agent 
and the G-quadruplex Structure have Sufficient chemical 
interaction to form a complex is roughly 75% of the favor 
able intermolecular interaction energy, calculated with the 
above programs, of the perylene diimide 2-d(TTAGGG) 
(SEQ ID No. 1) complex structure as determined by NMR 
SpectroScopy. 
Preferred G-quadruplex structures are those formed by the 
sequences d(TTAGGG) (SEQ ID No. 1), d(AATGGGT), 
(SEQ ID No. 5) and d(TTAGGGTT) (SEQ ID No. 4). 
Several methods of determining the interaction of potential 
G-quadrupleX interactive agents with these structures 
include UV/VIS spectroscopy, in which the changes in the 
UV/VIS spectrum of the potential agent under more than a 











which undergoes the most change, upon addition of an 
excess of the G-quadruplex Structure, UV spectroscopy, in 
which the melting temperature of the G-quadruplex Structure 
as determined by a hyperchromicity transition at a given 
temperature range is increased by >50 C. upon addition of 
an excess of the agent; UV/VIS spectroscopy in which 
addition of a potential G-quadrupleX interactive agent to a 
complex of a G-quadruplex-interactive perylene diimide and 
a G-quadruplex produces a >25% change in the absorption 
of due to the G-quadruplex-interactive perylene dimine-G- 
quadruplex complex; UV/VIS spectroscopy in which addi 
tion of a potential G-quadruplex interactive agent to a 
complex of a G-quadruplex-interactive carbocyanine and a 
G-quadruplex produces a >25% change in the absorption of 
due to the G-quadruplex-interactive carbocyanine-G- 
quadruplex complex; NMR spectroscopy in which the melt 
ing temperature of the G-quadruplex as determined by the 
disappearance of the imino proton Signals of the 
G-quadruplex is increase by >5 C. in the presence of one 
to two-equivalents of the agent; NMR spectroscopy in which 
the interaction of the agent with the G-quadruplex Structure 
is determined by the shift of at least one of the imino protons 
of the G-quadruplex by >0.01 ppm upon addition of one- to 
two-equivalents of the agent, fluorescence Spectroscopy in 
which the fluorescence emission spectrum of the agent 
undergoes a shift of >5 nm and/or a change in intensity of 
>25% upon the addition of an excess of the G-quadruplex 
Structure; fluorescence SpectroScopy in which the fluores 
cence emission Spectrum of a G-quadruplex-interactive 
perylene diimide-G-quadruplex complex undergoes a >25% 
change upon the addition of an excess of the agent; or 
fluorescence spectroScopy in which the fluorescence emis 
Sion Spectrum of a G-quadruplex-interactive carbocyanine 
G-quadruplex complex undergoes a >25% change upon the 
addition of an excess of the agent. 
The preferred embodiments of the invention as it related 
to one class of G-quadrupleX interactive telomerase inhibi 
tors are compounds of the Structure I in which 
in which R" and R" are independently taken from the set of 
Sub-structures given by the formula -L-A in which L is a 
linking group taken from the Set consisting of: 
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where n is 1, 2, or 3; and each R5 is independently taken 
from the set H, Me, OH, or OMe; 
RS R5 
S1 
where R5 is as before and Y is taken from the set O, S, SO, 
SO2, NH, NMe, NCOMe; 
XCX) 2 Y S1 
where R5 and Y are as before and X is taken from the set 
CH2, O, S, SO, SO2, NH, NMe, NCOMe, 
where R6, R7, R8, and R9 are independently taken from the 
set consisting of H, OMe, OEt, halo, or Me; 
or a bond; 
and A is taken from the Set consisting of: 
where m is 0–5 and each R6 is taken from the set consisting 
of halo, NH2, NO2, CN, OMe, SO2NH2, amidino, 
guanidino, or Me, 
R', Stre )q 
where o is 0 or 1; p is 0, 1, or 2, q is 1 or 2. Such that O--q 
is either 2, in which case a pyrrolidine or pyrrole ring is 
indicated, or 3, in which a piperidine or pyridine ring is 
indicated; r is 0, 1, 2, or 3; R7 is H or Me; each R8 is 
independently taken from the set consisting of Me, NO2, 
OH, CH2OH, halo, or when r is 2 or 3, two adjacent R8 
substituents may be together taken as -(CH=CH)2- or 










where each R9 is independently taken from the set consist 
ing of H, Me, or both R9 can taken together be =O; S is 
equal to 0 or 1; and Z is taken from the Set consisting of 
CH2, O, NH, NMe, NEt, N(Me)2, N(Et)2, or NCO2Et; 
O R10 
-(OC X R11 
where Q is either N, CH, NMe, or NEt; X is either O, S, NH, 
NMe or NEt; R10 and R11 are independently taken from the 
set consisting of H, Me, CH2CO2Et, or R10 and R11 taken 
together consist of -(CH=CH)2- or -(CH2)4-, 
12 
2-R's 3. 
where t is equal to 1, 2, 3, or 4., u is equal to 0, 1, 2, 3, or 
4, and each R12 is individually taken from the Set consisting 
of Me, or OH: 
ro, 
OH, CO2R, CONCR), SO3H, SO2N(R'), CN, 
CH(CO2R), CH(CON(R).), N(R'), or N(R'), 
where R13 is either H, Me, Et, or CHCH-OH: 
R2, R2, R2", R2"; R3, R3', R3", R3" are each indepen 
dently taken from the set H, OMe, halo, or NO2. 
In addition, this invention includes the development of 
other G-quadrupleX interactive telomerase inhibitors com 
pounds derived from Structure I, having the following Struc 
tureS: 
or 33 ?o 'Rs 5, 
v . . . /), () )-( )-() ( ( ) O O 
The preferred embodiment of the invention as it relates to 
another class of G-quadruplex interactive telomerase inhibi 
tors are compounds of the general Structure II: 




X-c={O B B 
in which C is either a bond, -CH=CH-, -(CH=CH) 
2-, -(CH=CH)3-, p-phenylene, o-phenylene, 
p-phenylene-CH=CH-, or o-phenylene-CH=CH-; B is 
O, S, or NR, and R is either Me or Et. 
In addition, this invention includes the development of 
another G-quadrupleX interactive telomerase inhibitor com 
pound derived from Structure H, having the following Struc 
ture: 
r" 
BRIEF DESCRIPTION OF THE DRAWINGS 
The following drawings form part of the present Specifi 
cation and are included to further demonstrate certain 
aspects of the present invention. The invention may be better 
understood by reference to one or more of these drawings in 
combination with the detailed description of Specific 
embodiments presented herein. 
FIG. 1. Effect of increasing concentrations of N,N'-bis(2- 
dimethylaminoethyl)-3,4,9,10-perylenetetracarboxylic acid 
diimide on inhibition of telomerase catalyzed extension of 
an 18-mer primer dTTAGGG) (SEQ ID No. 1) (1 uM). 
Elongated primer was labeled with 1.5uM of O.--P-dGTP 
(800 Cimmol, 10 mCiml) with 1 mM dATP and dTTP 
using a Standard telomerase assay. Lanes 1-5 are 0, 10, 50, 
and 100 uM of N,N'-bis(2-dimethylaminoethyl)-3,4,9,10 
perylenetetracarboxylic acid diimide. 
FIG. 2. Changes in the UV/VIS absorbance spectrum of 
N,N'-bis(2-dimethylamino ethyl)-3, 4,9,10 
perylenetetracarboxylic acid diimide upon addition of 
increasing amount ofd(TTAGGGT) (SEQ ID No. 6), an 
oligodeoxyribonucleotide which adopts a G-quadruplex 
Structure. 
FIG. 3. Titration ofd(TTAGGGy) (SEQ ID No. 1) with 
N,N'-bis(2-piper dino ethyl)-3, 4, 9, 10 
perylenetetracarboxylic acid diimide. Imino proton region of 
the 500-MHz 1H NMR is shown with increasing amounts of 
added ligand. The resonances labeled G4, G5*, and G6* 
represent resonances of final 2:1 ligand/G-quadruplex com 
plexes. 
FIG. 4. NMR-based model of d(TTAGGG) (SEQ ID 
No. 1) - N,N'-bis(2-piper dino ethyl)3, 4,9,10 
perylenetetracarboxylic acid diimide complex. The ligand is 
Stacked under the G6 guanine tetrad with positively charged 
Side chains located in the grooves. 
FIG. 5. Shows the design of an intramolecular quadruplex 











FIG. 6. Photocleavage of G4A DNA by TMPyP4 in K" 
buffer. 
FIG. 7. Model depicting G-quadruplex structure blocking 
primer extension by DNA polymerase. 
FIG.8. Primer extension of PQ sequence in the presence 
of compounds. Lane 1: water control; Lane 2: 50 mM K+; 
Lanes 3-6, QQ23; Lanes 7-10; OO30; Lanes 11-14, OO31; 
Lanes 15-18; APPER (Bis1-(2-aminoethyl)piperdine-3, 4, 
9, 10-perylenetetracarboxylic diimide); Lanes 3, 7, 11, and 
15; 0.5 uM; Lanes 4, 6, 12,and 16; 1 uM; Lanes 5, 9, 13 and 
17; 10 uM; Lanes 6, 10, 14 and 18; 50 uM. 
DETAILED DESCRIPTION OF PREFERRED 
EMBODIMENTS 
I. The Present Invention 
A Structure-based approach to discovering non-nucleoside 
compounds that will selectively inhibit human telomerase by 
targeting the nucleic acid Structures, Such as 
G-quadruplexes, that may be associated with human telom 
eres or telomerase has been utilized. Inhibition of human 
telomerase by a 2,6-diamido anthraquinone has been Suc 
cessfully demonstrated. 'H-NMR has demonstrated the sta 
bilization of a G-quadruplex by this compound and evidence 
has been provided that this compound inhibits the telom 
erase enzyme by a mechanism consistent with interaction 
with G-quadruplex Structures. The present work Shows that 
non-nucleoside, Small molecules can interact with 
G-quadruplexes and inhibit telomerase. 
Using the methods described, it was found that com 
pounds that bind to the human G-quadruplex Structure 
inhibit the human telomerase. The identification of Such 
G-quadruplex interactive agents is a novel and efficient 
approach for identifying human telomerase inhibitors. 
It is envisioned that the telomerase inhibitors will provide 
therapy for tumors and cancers including skin cancers, 
connective tissue cancers, adipose cancers, breast cancers, 
lung cancers, Stomach cancers, pancreatic cancers, OVarian 
cancers, cerVical cancers, uterine cancers, anogenital 
cancers, kidney cancers, bladder cancers, colon cancers, 
prostate cancers, central nervous System (CNS) cancers, 
retinal cancer, blood, lymphoid cancers and the like. 
II. Telomerase 
Telomerase is a ribonucleoprotein enzyme that Synthe 
sizes one Strand of the telomeric DNA using as a template a 
Sequence contained within the RNA component of the 
enzyme. The ends of chromosomes have Specialized 
Sequences, termed telomeres, comprising tandem repeats of 
simple DNA sequences which in humans is 5'-TTAGGG 
(SEQ ID No. 1) (Blackburn, 1991; Blackburn et al., 1995). 
Apart from protecting ends of chromosomes telomeres have 
Several other functions, the most important of which appear 
to be associated with replication, regulating the cell cycle 
clock and ageing (Counter et al., 1992). Progressive rounds 
of cell division shorten telomeres by 50-200 nucleotides per 
round. Almost all tumor cells have shortened telomeres, 
which are maintained at a constant length (Allshire et al., 
1988; Harley et al., 1990; Harley et al., 1994) and are 
asSociated with chromosome instability and cell immortal 
ization. 
With regard to human cells and tissueS telomerase activity 
has been identified in immortal cell lines and in ovarian 
carcinoma but has not been detected at biologically signifi 
cant levels (that are required to maintain telomere length 
over many cell divisions) in mortal cell Strains or in normal 
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non-germline tissues (Counter et al., 1992; Counter et al., 
1994). These observations Suggest telomerase activity is 
directly involved in telomere maintenance, linking this 
enzyme to cell immortality. 
AS described above, the immortalization of cells involves 
the activation of telomerase. More Specifically, the connec 
tion between telomerase activity and the ability of many 
tumor cell lines, including skin, connective tissue, adipose, 
breast, lung, Stomach, pancreas, Ovary, cervix, uterus, 
kidney, bladder, colon, prostate, central nervous System 
(CNS), retina and blood tumor cell lines, to remain immortal 
has been demonstrated by analysis of telomerase activity 
(Kim, et al., 1994). This analysis, supplemented by data that 
indicates that the Shortening of telomere length can provide 
the Signal for replicative Senescence in normal cells, See 
PCT Application No. 93/23572, incorporated herein by 
reference, demonstrates that inhibition of telomerase activity 
can be an effective anti-cancer therapy. Thus, telomerase 
activity can prevent the onset of otherwise normal replica 
tive Senescence by preventing the normal reduction of 
telomere length and the concurrent cessation of cell repli 
cation that occurs in normal Somatic cells after many cell 
divisions. In cancer cells, where the malignant phenotype is 
due to loSS of cell cycle or growth controls or other genetic 
damage, an absence of telomerase activity permits the loSS 
of telomeric DNA during cell division, resulting in chromo 
Somal rearrangements and aberrations that lead ultimately to 
cell death. However, in cancer cells having telomerase 
activity, telomeric DNA is not lost during cell division, 
thereby allowing the cancer cells to become immortal, 
leading to a terminal prognosis for the patient. 
Methods for detecting telomerase activity, as well as for 
identifying compounds that regulate or affect telomerase 
activity, together with methods for therapy and diagnosis of 
cellular Senescence and immortalization by controlling 
telomere length and telomerase activity, have also been 
described elsewhere. 
A. G-Quadruplex Structures 
Human telome reS form Structures known as 
G-quadruplexes. Human telomeres contain numerous 
repeats of the sequence TTAGGG (SEQ ID No. 1), exhib 
iting an enhancement of G and T residues and a paucity of 
A residues. Intramolecular G-quadruplex DNA may be 
designed by generating a sequence of human telomere 
repeats (FIG. 5). The G tetrad consists of four G bases 
hydrogen bonded in Hoogsteen fashion Symmetrically dis 
posed about a central axis, as shown in FIG. 5. 
G-rich DNA is known to assume highly stable structures 
formed by Hoogsteen base pairs between guanine residues 
(Williamson, 1994; Nadel et at., 1995). These structures, 
known as G-quadruplexes, are Stabilized in the presence of 
Kand may have biological roles that are yet to be deter 
mined (Henderson et at., 1987; Hardin et at., 1997; Will 
iamson et at., 1989). One particular region of the genome 
where these Structures may play a significant biological role 
is at the ends of chromosomes where G-rich DNA is 
normally found (e.g., TTAGGG (SEQ ID No. 1) and 
TTGGGG (SEQ ID No. 7) tandem repeats in human cells 
and ciliate Tetrahymena, respectively) (Henderson et at., 
1987; Blackburn and Greider, 1995; Sundquist and Heaphy, 
1993). In addition, a number of genes containing G-rich 
DNA have been identified recently, and it has been proposed 
that the G-rich regions within these genes may regulate gene 
expression by forming G-quadruplex structures (Sen and 











Lilley, 1992; Simonsson et al., 1998). One potential biologi 
cally relevant role of G-quadruplex DNA is as a barrier to 
DNA synthesis (Howell et al., 1996). This barrier has been 
thoroughly investigated and has been found to be 
K"dependent (Woodword et at., 1994). This observation 
Strongly Suggests that the formation of G-quadrupleX Species 
is responsible for the observed effect on DNA synthesis 
(Weitzmann et al., 1996). 
The inventors have shown that the 2, 6 
diamidoanthraquinone BSU-1051 modulates human telom 
erase activity by a mechanism that is dependent on the 
elongation of the telomeric primer d(TTAGGG) (SEQ ID 
No. 1) to a length that is then capable of forming an 
intramolecular G-quadruplex structure (Sun et al., 1997). 
The inventors have also shown that BSU-1051, by virtue of 
its interaction with G-quadruplex DNA, enhances the block 
of DNA synthesis by the G-quadruplex structure in the 
presence of K". 
B. Methods for Identifying G-quadruplex 
Interactive Agents 
Several methods for identifying classes of G-quadruplex 
interactive agents may be employed. One method involves 
identifying compounds whose three-dimensional Structure is 
complementary to that of the G-quadruplex Structure. 
G-quadruplex Structure is understood to mean at least in one 
Sense the Structure of the G-quadruplex that is formed by the 
Single-Stranded DNA corresponding to at least four repeats 
of the telomeric Sequence. In humans, the telomeric 
sequence is d(TTAGGG) (SEQ ID No. 1). Thus, the 
G-quadruplex Structure of interest for the identification of 
human telomerase inhibitors may be any Sequence of the 
form {d(NITTAGGGNI) (SEQ ID No. 1) where N.) 
is Zero to two bases corresponding to the human telomeric 
Sequence; for example, N may equal G, GG, or may be 
absent; where N is Zero to three bases corresponding to 
the human telomeric sequence; for example, N can equal 
T, TT, TTA or it may be absent. 
Alternatively, G-quadruplex Structure is understood to 
mean the fold-over or intramolecular G-quadruplex formed 
from at least four repeats of the G-triad of telomeric 
Sequence. Thus, the G-quadruplex Structure of interest for 
the identification of human telomerase inhibitors may be any 
sequence of the form d(INTTAGGGIN) (SEQ ID No. 
1 where N is as defined above and N is three G's 
preceded by Zero to three nucleotides corresponding to the 
human telomeric Sequence. These structures may be deter 
mined by a variety of techniques including molecular 
mechanics calculations, molecular dynamics calculations, 
constrained molecular dynamicS calculations in which the 
constraints are determined by NMR spectroScopy, distance 
geometry in which the distance matrix is partially deter 
mined by NMR spectroscopy, X-ray diffraction, or neutron 
diffraction techniques. In the case of all these techniques, the 
Structure can be determined in the presence or absence of 
any ligands known to interact with G-quadruplex Structures, 
including but not limited to potassium and other metal ions, 
2,6-diamidoanthraquinones, perylene diimides, or carbocya 
CS. 
Complementary is understood to mean the existence of a 
chemical attraction between the G-quadruplex interactive 
agent and the G-quadruplex. The chemical interaction may 
be due to one or a variety of favorable interactions, including 
ionic, ion-dipole, dipole-dipole, Van der Waals, charge 
transfer, and hydrophobic interactions. Each of these type of 
interactions, alone or together, may be determined by exist 
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ing computer programs using as inputs the Structure of the 
compound, the Structure of the G-quadruplex, and the rela 
tive orientation of the two. Such computer programs include 
but are not limited to AMBER, CHARMM, MM2, SYBYL, 
CHEMX, MACROMODEL, GRID, and BioSym. Such pro 
grams are contemplated as being useful for the determina 
tion of the chemical interaction between two molecules, 
either isolated, or Surrounded by Solvent molecules, Such as 
water molecules, or using calculational techniques that 
approximate the effect of Solvating the interacting mol 
ecules. The relative orientation of the two can be determined 
manually, by Visual inspection, or by using other computer 
programs which generate a large number of possible orien 
tations. 
Examples of computer programs include but are not 
limited to DOCK and AutoDOCK. Each orientation can be 
tested for its degree of complementarity using the computer 
programs. An advantage of this method is that it does not 
require availability of physical Samples of the compounds, 
only that their three-dimensional Structure is known. It thus 
can be used to design novel compounds that possess the 
desired ability to inhibit telomerase. 
Alternatively, this method may be used as a Screening 
method for identifying telomerase inhibitors from a collec 
tion of compounds that are available, provided that the 
Structure of these compounds is known. If only the two 
dimensional Structure is known, the corresponding three 
dimensional Structure can be obtained using existing com 
puter programs. Such computer programs include but are not 
limited to CONCORD, CHEM3D, and MM2. 
Another method for identifying G-quadruplex interactive 
compounds that may inhibit telomerase involves use of 
techniques such as UV/VIS spectroscopy, polarimetry, CD 
or ORD spectroscopy, IR or Raman spectroscopy, NMR 
Spectroscopy, fluorescence Spectroscopy, HPLC, gel 
electrophoresis, capillary gel electrophoresis, dialysis, 
refractometry, conductometry, atomic force microScopy, 
polarography, dielectometry, calorimetry, Solubility, EPR or 
mass spectroScopy. The application of these methods can be 
direct, in which the G-quadrupleX interactive compounds 
interaction with the G-quadruplex is measured directly, or it 
can be indirect, in which a particular G-quadruplex interac 
tive agent having a useful Spectroscopic property is used as 
a probe for the ability of other compounds to bind to the 
G-quadruplex; for example, by displacement or by fluores 
cence quenching. 
III. Telomerase Inhibitors 
The identification of compounds that inhibit telomerase 
activity provides important benefits to efforts at treating 
human disease. Compounds that inhibit telomerase activity 
can be used to treat cancer, as cancer cells express telom 
erase activity and normal human Somatic cells do not 
express telomerase activity at biologically relevant levels 
(i.e. at levels Sufficient to maintain telomere length over 
many cell divisions). Unfortunately, few Such compounds 
have been identified and characterized. Hence, there remains 
a need for compounds that act as telomerase inhibitors and 
for compositions and methods for treating cancer and other 
diseases in telomerase activity is present abnormally. The 
present invention meets these and other needs. 
Once a compound has been identified as being a 
G-quadruplex interactive agent, confirmatory evidence for 
the ability of said compound to inhibit telomerase may be 
obtained using a Standard primer extension assay that does 











primer extension products Such as described in Sun et al., 
1997. The identified inhibitors may be used therapeutically 
to interfere with the function of telomerase and thus to treat 
CCCS. 
Using the Screening methods described above, com 
pounds have been identified that bind to human 
G-quadruplex Structures and have been shown to inhibit 
human telomerase. One group of compounds is represented 
by general Structure I: 
in which R" and R' are represented by L-A where L is a 
linking group which may be any of a group of Substituted 
(X) methylene, (X) dimethylene, (X) trimethylene, 
(X) dimethylene a mine, (X) dimethylene oxy, 
(X) dimethylene a mino dimethylene, (X) - 
dimethyleneoxydimethylene, (X)-p-phenylene, (X)-m- 
phenylene, (X)-O-phenylene, or an unsubstituted covalent 
bond; 
A is a group that interacts with the grooves of the 
G-quadruplex Structure, examples being a Substituted car 
bocyclic ring, a (Substituted) heterocyclic ring, an hydroxyl, 
a carboxylic acid, a carboxylic acid ester, a carboxamide, a 
Sulfonamide, a Sulfonic acid, a nitrile, a malonate diester, a 
malonate diamide, a disubstituted amine, a quarternized 
nitrogen-containing heterocyclee, or a quaternary amine. 
R2, R2, R2", R2", R3, R3, R3", R3" are independently 
hydrogen, alkyl, halo, amino, nitro, hydroxy, alkoxy, 
alkylamino, dialkylamino, aryl, or cyano. 
Another group of compounds Suitable as telomerase 
inhibitors is shown by the general structure II in which B is 
O, S, or NR; C is an unsaturated linking group, 1 to 3 
(Substituted) ethylene groups, a Substituted or unsubstituted 







These compounds may interact Specifically with 
G-quadruplex Structures as compared to other nucleic acid 
Structures Such as double-Stranded DNA, Single-Stranded 
DNA, and RNA structures. The degree of selectivity in the 
interaction of these compounds with G-quadruplex Struc 
tures versus other nucleic acid Structures is given by the ratio 
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of the affinity of these compounds for G-qudruplex Struc 
tures to the affinity for the other nucleic acid structures. In 
particular, the ability of these compounds to distinguish 
between G-quadruplex structures and double-stranded DNA 
may be an important criterion. Compounds with general 
ability to bind double-stranded DNA are known to inhibit or 
alter a variety of DNA-associated enzymes or proteins, 
including but not limited to: histone binding, topoisomerase 
I, topoisomerase II, DNA-polymerases, RNA-polymerases, 
DNA repair enzymes, cytosine methyltransferase, and tran 
Scription factor binding. In order to discover compounds that 
are able to selectively inhibit telomerase and other 
G-qudruplex-associated enzymes and proteins, one would 
want to Select compounds that have a high ratio of affinities 
for G-qudruplex structures versus double-stranded DNA. 
These Selective G-quadruplex-binding compounds can be 
identified by Selecting those G-quadruplex binding com 
pounds that display weak or no ability for binding to 
double-stranded DNA, as determined by UV/VIS 
Spectroscopy, polarimetry, CD or ORD Spectroscopy, IR or 
Raman spectroscopy, NMR spectroscopy, fluorescence 
Spectroscopy, HPLC, gel electrophoresis, capillary gel 
electrophoresis, dialysis, refractometry, conductometry, 
atomic force microscopy, polarography, dielectometry, 
calorimetry, Solubility, EPR and mass spectroScopy. 
In addition to the thermodynamic considerations of 
G-quadruplex binding by these compounds, the kinetics of 
the interaction between these compounds and 
G-quadruplexes is also considered to be important. The 
relative rates of the association and dissociation of these 
compounds with G-quadruplex Structures can affect their 
biological properties. In particular, those compounds with 
Slow dissociation rates may be more effective in inhibiting 
telomerase and other G-quadruplex-associated enzymes and 
proteins than hose with identical G-quadruplex binding 
ability, but whose dissociation rates are faster. For a given 
compound, the overall equilibrium binding affinity (binding 
constant) to G-quadruplex structures is a ratio of the asso 
ciation rate and the dissociation rate. The dissociation rate of 
a complex consisting of a G-quadruplex Structure and a 
G-quadruplex interactive compound can be determined by a 
variety of methods. In one example, the dissociation of the 
complex can be determined spectrophotometrically upon the 
addition of a detergent, such as SDS. Alternatively, the 
dissociation rate can be determined in a T-jump Study, in 
which the temperature of the complex is quickly raised to a 
point at which the complex dissociates and this process is 
monitored Spectrophotometrically. In another example the 
dissociation rate for a G-quadruplex-compound complex 
can be determined by monitoring by a variety of techniques 
the dissociation of a complex in which one partner, either the 
G-quadruplex or the compound, is tethered, either 
covalently or non-covalently, to an immobile phase, and a 
Solution is passed over this immobilized complex. The 
dissociation rate for a G-quadruplex-compound complex 
also can be determined indirectly, by measuring both the 
equilibrium binding constant and the association rate. For 
example, if two compounds have Similar equilibrium 
G-quadruplex binding constants, but one has a Slower asso 
ciation rate, then that Same compound must also have a 
proportionately slow dissociation rate. 
Using the above techniques, one can Select from those 
G-quadruplex interactive agents identified, those that have 
additional desired properties of Selective G-quadruplex 
interaction when compared to other nucleic acids Structures, 
Such as double-stranded DNA, and/or slow kinetics of 












Agents capable of inhibiting telomerase activity in tumor 
cells offer therapeutic benefits with respect to a wide variety 
of cancers and other conditions (for example, fungal 
infections) in which immortalized cells telomerase activity 
are a factor in disease progression or in which inhibition of 
telomerase activity is desired for treatment purposes. The 
telomerase inhibitors of the invention can also be used to 
inhibit telomerase activity in germ line cells, which may be 
useful for contraceptive purposes. 
IV. Pharmaceutical Formulations and 
Administration 
The invention further comprises the therapeutic treatment 
of cancer by the administration of an effective dose of one 
or more inhibitors of telomerase. Where clinical applications 
are contemplated, it will be necessary to prepare pharma 
ceutical compositions of drugs in a form appropriate for the 
intended application. Generally, this will entail preparing 
compositions that are essentially free of pyrogens, as well as 
other impurities that could be harmful to humans or animals. 
The phrase “pharmaceutically or pharmacologically 
acceptable” refer to molecular entities and compositions that 
do not produce adverse, allergic, or other untoward reactions 
when administered to an animal or a human. AS used herein, 
“pharmaceutically acceptable carrier includes any and all 
Solvents, dispersion media, coatings, antibacterial and anti 
fungal agents, isotonic and absorption delaying agents and 
the like. The use of Such media and agents for pharmaceu 
tically active Substances is well know in the art. Supple 
mentary active ingredients also can be incorporated into the 
compositions. 
The active compositions of the present invention may 
include classic pharmaceutical preparations. Administration 
of these compositions according to the present invention will 
be via any common route So long as the target tissue is 
available via that route. This includes oral, nasal, buccal, 
rectal, vaginal or topical. Alternatively, administration may 
be by orthotopic, intradermal, Subcutaneous, intramuscular, 
intraperitoneal or intravenous injection. Such compositions 
would normally be administered as pharmaceutically 
acceptable compositions, described Supra. A preferred route 
is direct intra-tumoral injection, injection into the tumor 
vasculature or local or regional administration relative to the 
tumor Site. 
The active compounds may also be administered parenter 
ally or intraperitoneally. Solutions of the active compounds 
as free base or pharmacologically acceptable Salts can be 
prepared in water Suitably mixed with a Surfactant, Such as 
hydroxypropylcellulose. Dispersions can also be prepared in 
glycerol, liquid polyethylene glycols, and mixtures thereof 
and in oils. Under ordinary conditions of Storage and use, 
these preparations contain a preservative to prevent the 
growth of microorganisms. 
The pharmaceutical forms Suitable for injectable use 
include Sterile aqueous Solutions or dispersions and Sterile 
powders for the extemporaneous preparation of Sterile 
injectable Solutions or dispersions. In all cases the form must 
be Sterile and must be fluid to the extent that easy Syring 
ability exists. It must be stable under the conditions of 
manufacture and Storage and must be preserved against the 
contaminating action of microorganisms, Such as bacteria 
and fungi. The carrier can be a Solvent or dispersion medium 
containing, for example, water, ethanol, polyol (for example, 
glycerol, propylene glycol, and liquid polyethylene glycol, 
and the like), Suitable mixtures thereof, and vegetable oils. 
The proper fluidity can be maintained, for example, by the 
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use of a coating, Such as lecithin, by the maintenance of the 
required particle size in the case of dispersion and by the use 
of Surfactants. The prevention of the action of microorgan 
isms can be brought about by various antibacterial an 
antifungal agents, for example, parabens, chlorobutanol, 
phenol, Sorbic acid, thimerosal, and the like. In many cases, 
it will be preferable to include isotonic agents, for example, 
SugarS or Sodium chloride. Prolonged absorption of the 
injectable compositions can be brought about by the use in 
the compositions of agents delaying absorption, for 
example, aluminum monoStearate and gelatin. 
Sterile injectable Solutions are prepared by incorporating 
the active compounds in the required amount in the appro 
priate Solvent with various of the other ingredients enumer 
ated above, as required, followed by filtered Sterilization. 
Generally, dispersions are prepared by incorporating the 
various Sterilized active ingredients into a Sterile vehicle 
which contains the basic dispersion medium and the 
required other ingredients from those enumerated above. In 
the case of Sterile powders for the preparation of Sterile 
injectable Solutions, the preferred methods of preparation 
are vacuum-drying and freeze-drying techniques which 
yield a powder of the active ingredient plus any additional 
desired ingredient from a previously Sterile-filtered Solution 
thereof. 
AS used herein, "pharmaceutically acceptable carrier' 
includes any and all Solvents, dispersion media, coatings, 
antibacterial and antifungal agents, isotonic and absorption 
delaying agents and the like. The use of Such media and 
agents for pharmaceutical active Substances is well known in 
the art. Except insofar as any conventional media or agent is 
incompatible with the active ingredient, its use in the thera 
peutic compositions is contemplated. Supplementary active 
ingredients can also be incorporated into the compositions. 
For oral administration the compounds developed in the 
present invention may be incorporated with excipients and 
used in the form of non-ingestible mouthwashes and denti 
frices. A mouthwash may be prepared incorporating the 
active ingredient in the required amount in an appropriate 
solvent, such as a sodium borate solution (Dobell's 
Solution). Alternatively, the active ingredient may be incor 
porated into an antiseptic wash containing Sodium borate, 
glycerin and potassium bicarbonate. The active ingredient 
may also be dispersed in dentifrices, including: gels, pastes, 
powders and slurries. The active ingredient may be added in 
a therapeutically effective amount to a paste dentifrice that 
may include water, binders, abrasives, flavoring agents, 
foaming agents, and humectants. 
The compositions of the present invention may be for 
mulated in a neutral or Salt form. Pharmaceutically 
acceptable Salts include the acid addition Salts (formed with 
the free amino groups of the protein) and which are formed 
with inorganic acids Such as, for example, hydrochloric or 
phosphoric acids, or Such organic acids as acetic, oxalic, 
tartaric, mandelic, and the like. Salts formed with the free 
carboxyl groups can also be derived from inorganic bases 
Such as, for example, Sodium, potassium, ammonium, 
calcium, or ferric hydroxides, and Such organic bases as 
isopropylamine, trimethylamine, histidine, procaine and the 
like. 
Upon formulation, Solutions will be administered in a 
manner compatible with the dosage formulation and in Such 
amount as is therapeutically effective. The formulations are 
easily administered in a variety of dosage forms Such as 
injectable Solutions, drug release capsules and the like. For 











example, the solution should be suitably buffered if neces 
Sary and the liquid diluent first rendered isotonic with 
Sufficient Saline or glucose. These particular aqueous Solu 
tions are especially Suitable for intravenous, intramuscular, 
Subcutaneous and intraperitoneal administration. In this 
connection, Sterile aqueous media which can be employed 
will be known to those of skill in the art in light of the 
present disclosure. For example, one dosage could be dis 
Solved in 1 ml of isotonic NaCl Solution and either added to 
1000 ml of hypodermoclysis fluid or injected at the proposed 
Site of infusion, (see for example, “Remington's Pharma 
ceutical Sciences' 15th Edition, pages 1035-1038 and 
1570–1580). Some variation in dosage will necessarily 
occur depending on the condition of the Subject being 
treated. The perSon responsible for administration will, in 
any event, determine the appropriate dose for the individual 
Subject. Moreover, for human administration, preparations 
should meet Sterility, pyrogenicity, general Safety and purity 
standards as required by FDA Office of Biologics standards. 
Because telomerase is active only in tumor, germline, and 
certain Stem cells of the hematopoietic System, other normal 
cells are not affected by telomerase inhibition therapy Steps 
also can be taken to avoid contact of telomerase inhibitor 
with germline or Stem cells, although this may not be 
essential. For instance, because germline cells express 
telomerase activity, inhibition telomerase may negatively 
impact Spermatogenesis and Sperm viability, Suggesting that 
telomerase inhibitors may be effective contraceptives or 
Sterilization agents. This contraceptive effect may not be 
desired, however, by a patient receiving a telomerase inhibi 
tor of the invention for treatment of cancer. In Such cases, 
one can deliver a telomerase inhibitor of the invention in a 
manner that ensures the inhibitor will only be produced 
during the period of therapy, such that the negative impact 
on germline cells is only transient. 
V. Therapies 
One of the major challenges in oncology today is the 
effective treatment of a given tumor. Tumors are often 
resistant to traditional therapies. Thus, a great deal of effort 
is being directed at finding efficOuS treatment of cancer. One 
way of achieving this is by combining new drugs with the 
traditional therapies and is discussed below. In the context of 
the present invention, it is contemplated that therapies 
directed against telomerase could be used in conjunction 
with Surgery, chemotherapy, radiotherapy and indeed gene 
therapeutic intervention. It also may prove effective to 
combine telomerase targeted chemotherapy with antisense 
or immunotherapies directed toward tumor markers or other 
oncogenes or oncoproteins. 
“Effective amounts' are those amounts of a candidate 
Substance effective to reproducibly decrease expression of 
telomerase in an assay in comparison to levels in untreated 
cells. An "effective amount” also is defined as an amount 
that will decrease, reduce, inhibit or otherwise abrogate the 
growth of a cancer cell. 
It is envisioned that the telomerase inhibitors will provide 
therapy for a wide variety of tumors and cancers including 
Skin cancers, connective tissue cancers, adipose cancers, 
breast cancers, lung cancers, Stomach cancers, pancreatic 
cancers, OVarian cancers, cervical cancers, uterine cancers, 
anogenital cancers, kidney cancers, bladder cancers, colon 
cancers, prostate cancers, central nervous System (CNS) 
cancers, retinal cancer, blood and lymphoid cancers. 
A. Combination Therapies 
To kill cells, inhibit cell growth, inhibit metastasis, inhibit 
angiogenesis or otherwise reverse or reduce the malignant 
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phenotype of tumor cells, the methods of Standard therapy 
discussed above are generally insufficient as tumors are 
often resistant to Several of these agents. Often combining a 
host of different treatment methods prove most effective in 
cancer therapy. Further, several AIDS afflicted patients have 
a higher risk of developing cancers. Combination therapy in 
these cases is required to treat AIDS as well as the cancer. 
Using the methods and compounds developed in the present 
invention, one would generally contact a "target” cell with 
a telomerase inhibitor and at least one other agent. These 
compositions would be provided in a combined amount 
effective to kill or inhibit proliferation of the cell. This 
proceSS may involve contacting the cells with the telomerase 
based therapy and the other agent(s) or factor(s) at the same 
time. This may also be achieved by contacting the cell with 
a single composition or pharmacological formulation that 
includes both agents, or by contacting the cell with two 
distinct compositions or formulations, at the same time, 
wherein one composition includes the telomerase based 
therapy and the other includes the agent. 
Alternatively, the telomerase inhibitor-based treatment 
may precede or follow the other agent treatment by intervals 
ranging from min to wk. In embodiments where the other 
agent and telomerase-based therapy are applied Separately to 
the cell, one would generally ensure that a significant period 
of time did not expire between the time of each delivery, 
Such that the agent and telomerase-based treatment would 
Still be able to exert an advantageously combined effect on 
the cell. In Such instances, it is contemplated that one would 
contact the cell with both modalities within about 12-24 h 
of each other and, more preferably, within about 6-12 h of 
each other, with a delay time of only about 12 h being most 
preferred. In Some situations, it may be desirable to extend 
the time period for treatment significantly, however, where 
several days (2, 3, 4, 5, 6 or 7) to several wk (1, 2, 3, 4, 5, 
6, 7 or 8) lapse between the respective administrations. 
It also is conceivable that more than one administration of 
either telomerase-based treatment or the other agent will be 
desired. Various combinations may be employed, where 
telomerase-based treatment is “A” and the other agent is 
“B”, as exemplified below: 
A/B/A B/A/B BABAA A/A/B BAA/A A/B/B BABAB/A 
B/B/A/B A/A/B/B A/B/A/B A/B/B/A BABAA/A B/A/B/A 
B/A/A/B B/B/B/A A/A/A/B B/A/A/A A/B/A/A A/A/B/A 
Other combinations are also contemplated. Again, to 
achieve cell killing, both agents are delivered to a cell in a 
combined amount effective to kill the cell. 
The invention also encompasses the use of a combination 
of one or more DNA damaging agents, whether chemothera 
peutic compounds or radiotherapeutics as described in the 
section below, together with the telomerase inhibitor. The 
invention also contemplates the use of the telomerase inhibi 
tors in combination with Surgical removal of tumors to treat 
any remaining neoplastic or metastasized cells. Further, 
immunotherapy may be directed at tumor antigen markers 
that are found on the Surface of tumor cells. The invention 
also contemplates the use of telomerase inhibitors in com 
bination with gene therapy, directed toward a variety of 
oncogenes, Such as, tumor markers, cell cycle controlling 
genes, described below. 
The other agent may be prepared and used as a combined 











telomerase-inhibitor based treatment, as described above. 
The skilled artisan is directed to “Remington's Pharmaceu 
tical Sciences' 15th Edition, chapter 33, in particular pages 
624–652. Some variation in dosage will necessarily occur 
depending on the condition of the Subject being treated. The 
perSon responsible for administration will, in any event, 
determine the appropriate dose for the individual Subject. 
Moreover, for human administration, preparations should 
meet Sterility, pyrogenicity, general Safety and purity Stan 
dards as required by FDA Office of Biologics standards. 
It is proposed that the regional delivery of non-nucleoside 
inhibitors of telomerase to patients with tumors will be a 
very efficient method for delivering a therapeutically effec 
tive chemical to counteract the clinical disease. Similarly, 
other chemotherapeutics, radiotherapeutics, gene therapeu 
tic agents may be directed to a particular, affected region of 
the subjects body. Alternatively, systemic delivery of telom 
erase based treatment and/or the agent may be appropriate in 
certain circumstances, for example, where extensive 
metastasis has occurred. 
It also should be pointed out that any of the standard or 
other therapies may prove useful by themselves in treating 
a cancer. In this regard, reference to chemotherapeutics and 
non-telomerase inhibitor-based treatment in combination 
should also be read as a contemplation that these approaches 
may be employed Separately. 
When such combination therapy is employed for the 
treatment of a tumor, the cytotoxic agent may be adminis 
tered at a dosage known in the art to be effective for treating 
the tumor. However, the G-quadrupleX interaction com 
pounds may produce an additive or Synergistic effect with a 
cytotoxic agent against a particular tumor. Thus, when Such 
combination antitumor therapy is used, the dosage of 
G-quadruplex interaction compounds administered may be 
less than that administered when the cytotoxic agent is used 
alone. Similarly, for patients afflicted by AIDS, AZT/ 
protease inhibitors will be used with G-quadruplex interac 
tion compounds, or other herein mentioned therapeutic 
agent(s). Again the dosage of G-quadruplex interaction 
compounds or other conjunctively utilized agent, may be 
altered to Suit the AIDS treatment. 
Preferably, the patient is treated with G-quadruplex inter 
action compounds for about 1 to 14 days, preferably 4 to 14 
days, prior to the beginning of therapy with a cytotoxic 
agent, and thereafter, on a daily basis during the course of 
such therapy. Daily treatment with the telomerase inhibitor 
can be continued for a period of, for example, 1 to 365 days 
after the last dose of the cytotoxic agent is administered. 
This invention encompasses the use of telomerase 
inhibitorS-based cancer therapy for a wide variety of tumors 
and cancers affecting skin, connective tissues, adipose, 
breast, lung, Stomach, pancreas, Ovary, cervix, uterus, 
kidney, bladder, colon, prostate, anogenital, central nervous 
system (CNS), retina and blood and lymph. 
B. Standard Therapies 
Described herein are the therapies used as Standard or 
traditional methods for treatment of cancers. The Section on 
chemotherapy describes the use of non-nucleoside telom 
erase inhibitors as chemotherapeutic agents in addition to 
Several other well known chemotherapeutic agents. AS 
detailed in the section above, all the methods described 
below can be used in combination with the telomerase 
inhibitorS developed in the present invention. 
a. Surgery: Surgical treatment for removal of the cancer 
ous growth is generally a Standard procedure for the treat 
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ment of tumors and cancers. This attempts to remove the 
entire cancerous growth. However, Surgery is generally 
combined with chemotherapy and/or radiotherapy to ensure 
the destruction of any remaining neoplastic or malignant 
cells. 
b. Chemotherapy: A variety of chemical compounds, also 
described as “chemotherapeutic agents', function to induce 
DNA damage, are used to treat tumors. Chemotherapeutic 
agents contemplated to be of use, include, adriamycin, 
5-fluorouracil (5FU), etoposide (VP-16), camptothecin, 
actinomycin-D, mitomycin, cisplatin (CDDP), hydrogen 
peroxide, carboplatin, procarbazine, mechlorethamine, 
cyclophosphamide, ifosfamide, melphalan, chlorambucil, 
bisulfan, nitroSurea, dactinomycin, daunorubicin, 
doxorubicin, bleomycin, plicomycin, tamoxifen, taxol, 
transplatinum, Vincristin, vinblastin and methotrexate to 
mention a few. 
Agents that damage DNA include compounds that inter 
fere with DNA replication, mitosis and chromosomal Seg 
regation. Such chemotherapeutic compounds include 
adriamycin, also known as doxorubicin, etoposide, 
Verapamil, podophyllotoxin, and the like. Widely used in a 
clinical Setting for the treatment of neoplasms, these com 
pounds are administered through bolus injections intrave 
nously at doses ranging from 25-75 mg/m at 21 day 
intervals for adriamycin, to 35-50 mg/m for etoposide 
intravenously or double the intravenous dose orally. 
Agents that disrupt the Synthesis and fidelity of nucleic 
acid precursors and Subunits also lead to DNA damage. A 
number of Such agents have been developed, particularly 
useful are agents that have undergone extensive testing and 
are readily available. 5-fluorouracil (5-FU), is one such 
agent that is preferentially used by neoplastic tissue, making 
it particularly useful for targeting neoplastic cells. Thus, 
although quite toxic, 5-FU, is applicable with a wide range 
of carriers, including topical and even intravenous admin 
istrations with doses ranging from 3 to 15 mg/kg/day. 
Agents that directly cross-link nucleic acids, Specifically 
DNA, are envisaged to facilitate DNA damage leading to a 
useful antineoplastic treatment. For example, cisplatin, and 
other DNA alkylating agents may be used. Cisplatin has 
been widely used to treat cancer, with efficacious doses used 
in clinical applications of 20 mg/m for 5 days every three 
wk for a total of three courses. Cisplatin is not absorbed 
orally and must therefore be delivered via injection 
intravenously, Subcutaneously, intratumorally or intraperito 
neally. 
The non-nucleoside G-quadrupleX inhibitor compounds 
developed in this invention are chemotherapeutic agents that 
are cytotoxic and inhibit telomerase function which is criti 
cal to cell replication and maintenance of tumor cell immor 
tality. These compounds also indirectly inhibit DNA poly 
merases by their Strong interactions with the G-quadruplex 
structures (FIG. 7). 
c. Radiotherapy: Radiotherapeutic agents and factors 
include radiation and waves that induce DNA damage for 
example, Y-irradiation, X-rays, UV-irradiation, microwaves, 
electronic emissions, radioisotopes, and the like. Therapy 
may be achieved by irradiating the localized tumor Site with 
the above described forms of radiations. It is most likely 
that all of these factors effect a broad range of damage DNA, 
on the precursors of DNA, the replication and repair of 
DNA, and the assembly and maintenance of chromosomes. 
Dosage ranges for X-rays range from daily doses of 50 to 
200 roentgens for prolonged periods of time (3 to 4 wk), to 











radioisotopes vary widely, and depend on the half-life of the 
isotope, the Strength and type of radiation emitted, and the 
uptake by the neoplastic cells. 
d. Gene Therapy: Gene therapy based treatments targeted 
towards oncogenes such as p53, p16, p21, Rb, APC, DCC, 
NF-1, NF-2, BCRA2, p16, FHIT, WT-1, MEN-I, MEN-II, 
BRCA1, VHL, FCC, MCC, ras, myc, neu, raf, erb, Src, fms, 
jun, trk, ret, gsp, hst, bc1 and abl, which are often mutated 
versions of their normal cellular counterparts in cancerous 
tissues. 
VI. Screening for Anti-telomere and Anti-cancer 
Activity 
In particular embodiments, one may test the inhibitors by 
measuring their ability to inhibit growth of cancer cells, to 
induce cytotoxic events in cancer cells, to induce apoptosis 
of the cancer cells, to reduce tumor burden and to inhibit 
metastases. For example, one can measure cell growth 
according to the MTT assay. A significant inhibition in 
growth is represented by decreases of at least about 
30%-40% as compared to uninhibited, and most preferably, 
of at least about 50%, with more significant decreases also 
being possible. Growth assays as measured by the MTT 
assay are well known in the art. Other assays to measure cell 
death, apoptosis are well known in the art, for example, 
Mosmann et al., 1983; Rubinstein et al., 1990. 
Quantitative in vitro testing of the anti-tumor agents 
identified herein is not a requirement of the invention as it 
is generally envisioned that the agents will often be Selected 
on the basis of their known properties or by Structural and/or 
functional comparison to those agents already demonstrated 
to be effective. Therefore, the effective amounts will often be 
those amounts proposed to be Safe for administration to 
animals in another context. 
VII. EXAMPLES 
The following examples are included to demonstrate 
preferred embodiments of the invention. It should be appre 
ciated by those of skill in the art that the techniques 
disclosed in the examples which follow represent techniques 
discovered by the inventor to function well in the practice of 
the invention, and thus can be considered to constitute 
preferred modes for its practice. However, those of skill in 
the art should, in light of the present disclosure, appreciate 
that many changes can be made in the Specific embodiments 
which are disclosed and still obtain a like or similar result 
without departing from the Spirit and Scope of the invention. 
Example 1 
Telomerase Inhibition by N,N'-bis(2- 
dimethylaminoethyl)-3,4,9,10 
perylenetetracarboxylic acid dimide 
Selection of N,N'-bis(2-dimethylaminoethyl)-3,4,9,10 
perylenetetracarboxylic acid diimide as a potential telom 
erase inhibitor was determined by Method (B) as described 
in Example 2. 
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1. 
The relative inhibition of telomerase by N,N'-bis(2- 
dimethylaminoethyl)3,4,9,10-perylenetetracarboxylic acid 
diimide was determined in a Standard primer eXtension assay 
that does not use a PCRTM-based amplification of the telom 
erase primer extension products. Briefly, the 18-mer telom 
eric primer dTTAGGG) (SEQID No. 1) (1 uM) without or 
with N,N'-bis(2-dimethylaminoethyl)-3, 4,9, 
10-perylenetetracarboxylic acid diimide was elongated with 
telomerase in the presence of 1.5uM of O-PI-dGTP (800 
Cimmol, 10 mciml) with 1 mM dATP and 1 mM dTTP, 
The extension products were isolated and Visualized by 
autoradiography after denaturing gel electrophoresis. 
The ICso was determined to be 50 uM, and at 100 uM of 
N,N'-bis(2-dimethylamino ethyl)3, 4, 9, 10 
perylenetetracarboxylic acid diimide there is an almost 
complete inhibition of telomerase activity. N,N'-bis(2- 
piperdinoethyl)-3,4,9,10-perylenetetracarboxylic acid dim 





a 3 mM solution of d(TTAGGGT), (SEQ ID No. 6). After 
each addition the UV/VIS spectrum was recorded. Pro 
nounced changes in the UV/VIS spectrum of the compound 
were noted at wavelengths 488 nm (~40% hypochromicity), 
510 nm 50% hyperchromicity), and 548 nm (-200% 
hyperchromicity). 
(C) Compounds may be selected for their ability to 
interact with human DNA G-quadruplex as indicated by 
NMR spectroscopy. The imino proton spectrum (9-12 ppm) 
of a solution of d(TTAGGG)4 (SEQ ID No. 1) in D2O/H2O 
(10:90) was determined at 500 MHz. Aliquot of N,N'-bis(2- 
piperdinoethyl)-3,4,9,10-perylenetetracarboxylic acid dim 
ide were added and the imino proton Spectrum recorded. At 
an overall stoichiometry of 1:1 the G6 imino resonance 
becomes significantly broader and Shifts >0.2 ppm upfield. 
(D) Compounds may be selected for their ability to 
interact with human DNA g-quadruplex as indicated by an 
increase in the melting temperature of the G-quadruplex 
Structure. Thermal denaturation of the parallel four-Stranded 
G-quadruplex structure formed by the dTAGTI (7-mer) 
(125 mM KC1, 25 mM. KHPO, 1 mM EDTA, pH 6.9) 
monitored by NMR. The spectrum for DNA alone and in the 
presence of N,N'-bis(2-dimethylaminoethyl)-3,4,9,10 
perylenetetracarboxylic acid diimide. The molar ratio of 
N,N'-bis(2-dimethylamino ethyl)-3, 4,9,10 
perylenetetracarboxylic acid diimide to quadruplex was 4:1. 
The imino proton Signals have been assigned previously 
2 
)-()-() { O 383). 
Example 2 
Screening ASSays for Telomerase Inhibitors 
Compounds that inhibit telomerase are potential drugs for 
the treatment of cancer. The method Selects compounds 
based upon ability to interact with the human DNA-G- 
quadruplex. Several procedures for detecting this interaction 
include: 
(A) A three dimensional structure of a candidate com 
pound will be analyzed to determine their degree of comple 
mentarity to the three-dimensional Structure of human telo 
meric DNA G-quadruplex. The NMR solution structure of 
d(AGGGTTAGGGTTAGGGTTAGGG) (SEQ ID No. 8) 
pdb entry 143d and its corresponding molecular Surface, 
generated with the ms program, were used as inputs to the 
SPHGEN program. The resulting sphere cluster was used as 
input to DOCKv2.0 and a subset of the Cambridge crystal 
lographic database was Search using the contact Scoring 
algorithm. N,N'-bis(2-dimethylaminoethyl)-3,4,9,10 
perylenetetracarboxylic acid diimide was found to have one 
of the highest contact scores in the -2000 compounds 
examined. 
(B) Compounds may be selected for their ability to 
interact with human DNA G-quadruplex as indicated by 
UV/VIS spectroscopy. To a 10 uM solution of N,N'-bis(2- 
dimethylaminoethyl)-3,4,9,10-perylenetetracarboxylic acid 
diimide in 20 mM phosphate buffer containing 100 mM 







(Laughlan et al., 1994) as G6, G5, and G4 from high to low 
field. The presence of drug leads to line broadening and an 
upfield shift of the imino proton Signals indicative of inter 
calation. Furthermore, the melting temperature of the DNA 
G-quadrupleX is increased significantly in the presence of 
the compound. Spectra were acquired in 90% HO/10% 
DO on a Bruker AMX 500 MHz spectrometer at various 
15-85 C. using a 1-1 echo pulse sequence with a maxi 
mum excitation centered at 12.0 ppm. A total of 128 Scans 
was obtained for each spectrum with a relaxation delay of 2 
S. Before acquiring the Spectrum at each temperature, the 
Sample was allowed to equilibrate at the new temperature for 
at least 10 min. The data were processed with an exponential 
window function using 2 Hz of line broadening. The data 
indicate that N,N'-bis(2-dimethylaminoethyl)-3,4,9,10 
perylenetetracarboxylic acid diimide increases the melting 
temperature of the G-quadruplex by at least 20° C. 
Example 3 
Synthesis of N,N'-bis(2-piperdinoethyl)-3,4,9,10 
perylenetetracarboxylic acid dimide 
N,N'-bis(2-piper dino ethyl)-3, 4, 9, 10 
perylenetetracarboxylic acid dimide was prepared by mix 
ing three g of 3,4,9,10-perylenetetracarboxylic acid dianhy 
dride with 2.5 mL of 1-(2-aminoethyl)piperidine in 10 mL of 
DMA and 10 mL of 1,4-dioxane. The mixture was heated 
under reflux for 6 hours, and the solvents removed under 
reduced pressure. The residue was dissolved in -100 mL of 
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distilled water, and insoluble components were removed by 
filtration. The pH of the resulting solution was adjusted to -3 
with the addition of HCl, and the Solution was allowed to 
Stand overnight. Precipitated impurities was removed by 
filtration, and the resulting Solution was adjusted to pH1-12 
with the addition of NaOH. The precipitated product was 
isolated by filtration, washed with water and dried under 
WCUU. 
Example 4 
DNA Synthesis Arrest Assay 
It has been shown that DNA sequences with quadruplex 
forming potential present obstacles to DNA synthesis by 
DNA polymerases in a K" dependent manner. This K' 
dependent block to DNA polymerase is a selective and 
Sensitive indicator of the formation of intramolecular qua 
druplexes (Weitzmann, et al., 1996). This assay has been 
adapted to demonstrate the Stabilization of quadruplex by 
Small molecules and used to Screen potential G-quadruplex 
interactive compounds. 
The assay is a modification of that described by 
Weitzmann, et al. Briefly, primers (24 nM, sequence: 
5'-TAATACGACTCACTATAG-3) (SEQ ID No. 9) labeled 
with Y-PATP were mixed with template DNA PO74(12 
nM, 





ID No. 10) in a Tris-HCl buffer (10 mM Tris, pH 8.0) 
containing 5 mM K'and heated at 90° C. for 4 min. After 
cooling at room temperature for 15 min. potential 
G-quadruplex-interactive compounds were then added to 
various concentrations. The primer extension reactions were 
initiated by adding dNTP (final concentration 100 uM), 
MgCl (final concentration 3 mM) and Taq polymerase (2.5 
U/reaction, Boehringer Mannheim). The reactions were 
incubated at 55 C. for 15 mm. then stopped by adding an 
equal volume of stop buffer (95% formamide, 10 mM 
EDTA, 10 mM NaOH, 0.1% xylene cyanol, 0.1% bro 
mophenol blue). The products were separated on a 12% 
polyacrylamide Sequencing gel. The gels were then dried 
and visualized on a phosphorimager (Molecular Dynamics 
model 445 S1). 
To validate the assay, G-quadruplex interactive com 
pounds Such as porphyrins and perylenes were tested. The 
results were consistent with NMR and telomerase inhibition 
data. FIG. 8 shows the DNA synthesis arrest induced by 
Quinobenzoxazine analogs (QQ23, 1130, QQ31) and a 
perylene compound (APPER). 
Example 5 
Photocleavage Assay to Detect Quadruplex DNA 
Interactions 
(i) Design and Synthesis of an Intramolecular 
Quadruplex DNA 
The oligonucleotide G4A employed was Synthesized on a 
Perseptive DNA synthesizer and deprotected following the 
routine phosporamidite procedures. the DNA was purified 
by polyacrylamide gel electrophoresis (PAGE). The 
sequence for this 39 oligomer single strand DNA is: 
5' CATGGTGGTTTGGGTTAGGGTTAGGGT 












This human telomere repeat-containing DNA was 
designed to form an intramolecular quadruplex which can be 
stabilized by the stem region in (FIG. 5). A sticky end was 
added So that unusual Secondary Structures could be detected 
by ligation assay once they are formed. 
(ii) Photocleavage ASSay 
The G4A DNA was labeled with 'P at the 5' end and 
stored in 1xTE buffer at 3000 cpmful. For each photocleav 
age reaction, 10u of DNA (~5 ng) was mixed with 10 ul of 
200 mM KCl or 200 mM NaCl and boiled for 10 min before 
cooled down to room temperature. For the no porphyrin 
control Samples, 10 ul of distilled water was added instead. 
The mixtures were transferred to a 96 well plate and added 
with 2 ul of 1 M TMPyP4 aqueous solution. The samples 
were then exposed to 24 watts fluorescent daylight under a 
glass filter for different periods of time. Then the reactions 
were stopped with 100 ul of calf thymus DNA (0.1 ug/ul). 
After phenol-chloroform extraction, the Samples were Sub 
jected to Strand breakage treatment and ethanol precipita 
tion. The DNA samples were loaded onto a 16% polyacry 
lamide gel for electrophoresis and Visualized with 
Phosphorimager (from Molecular Dynamics, Inc.). A typical 
result for the photocleavage assay is shown in FIG. 6. 
Example 6 
Selection of G-Quadruplex Selective Ligand 
The N,N'-bis(3 -morpholinopropyl)3,4,9,10 
perylenetetracarboxilic acid diimide (KeTELO1) was syn 
thesized from 3,49,10-perylenetetracarboxylic acid dianhy 
dride and 3-morpholinopropylamine using a procedure 
analogous to that described above in example 5.3 for the 
synthesis of N,N'-bis(2-piperdinoethyl)-3,4,9,10 
perylenetetracarboxylic acid diimide. A Solution of 
KeTELO1 was prepared by dissolving 1 mg of KeTELO1 in 
300 uL of 1 NHCl. To this solution was added 11 mL of a 
pH 7.0 buffer containing 20 mM sodium phosphate, 100 mM 
KC1, 1 mM EDTA, and 0.02% hydroxypropyl-B- 
cyclodextrin. Aliquots of this stock solution of KeTELO1 
were transferred to 8 different quartz cuvettes and diluted 
into pH 7.0 mM sodium phosphate, 100 mM KCl, 1 mM 
EDTA buffer to afford Solutions in which the concentration 
of KeTELO1 was 20 uM. To each of the cuvettes was added 
a solution of d(TTAGGGT)4 (SEQ ID No. 6) so that the 
final concentration of d(TTAGGGT)4 (SEQ ID No. 6) in 
each of the cuvettes was 0.4, 8, 12, 16, 20, 50, and 80 uM. 
These Solutions were allowed to Stand overnight in the dark, 
and the UV/VIS spectrum of each was determined. 
Pronounced, G-quadruplex concentration-dependent 
changes in the UV/VIS spectrum were noted at wavelengths 
488 nm (~40% hypochromicity), 510 nm (~40% 
hyperchromicity) and 548 nm (~100% hyperchromicity). In 
a parallel study, changes in the UV/VIS spectrum of a 20 uM 
solution of KeTELO1 in a pH 7.0 20 mM phosphate buffer 
containing 100 mM KCl and 1 mM EDTA were determined 
upon the addition of 10 uMaliquots of a 3 mM (base pair) 
solution of calf thymus DNA. No changes in the UV/VIS 
Spectrum of this Solution were noted, indicating that 
KeTELO1 does not interact with double-stranded DNA. 
Example 7 
Kinetics of Interaction of KeTELO1 with G 
Quadruplex DNA 
A solution of 5 uM KeTELO1 in 20 mM phosphate buffer, 
100 mM KCl, pH 7.0 was placed in a quartz cuvette and the 
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UV/VIS spectrum determined. An aliquot of a solution of 
d(TTAGGGT)4 (SEQ ID No. 6) was added to the cuvette 
to afford a final concentration of 50 uM. The cuvette was 
quickly inverted Several times and placed in the Spectropho 
tometer. The absorption of the sample at 488 nm was 
continuously monitored for 3 hours, during which time, the 
absorption decreased in a multiexponential function. The 
time required for the absorption at 488 nm to reach one-half 
of its equilibrium value was 60 min. 
Example 8 
Telomerase Inhibition by UT-SK-02 
(Diethylthiocarbocyanine Iodide) 
Using the DOCK screening methods above, the carbocya 
nine group of compounds were identified as potential 
G-quadruplex interactive agents. A number of these com 
pounds were assayed using the DNA Synthesis Arrest ASSay 
described in example 5.4. Each compound was assayed at a 
concentration of 20 uM. The results of this study are 
Summarized in Table 1 ahead: 
TABLE 1. 
Stop Stop 
Compound (F + P)* (P/T) * * 
IBT 129A 68% 91% 
UTSK-OO1 86% 83% 
UTSK-OO2 88% 139% 
UTSK-OO3 29% 32% 
UTSK-004 71% 88% 
UTSK-OO6 33% 12% 
*Relative amount of both full-length and paused products. 
**Relative ratio of the amount of paused products as compared to the total 
amount of products. 
Of the compounds tested, only one, UT-SK-002 
(diethylthiocarbocyanine iodide) demonstrated a specific 
interaction with G-quadruplex DNA, as indicated by a 
relative ratio of paused to total DNA product greater than 
100% and a relative amount of DNA products, both paused 
and full length, that is close to 100%. In confirmatory tests, 
only this compound inhibited telomerase, with an inhibition 
of 10-35% at a concentration of 50 uM. 
Example 9 
Reduced Cellular Proliferation by Selected 
Compounds 
The ability of these compounds to inhibit the proliferative 
capacity of human cancer cells was determined by a stan 
dard MTT assay. Briefly, cells were incubated for 72 hours 
in the presence of various concentrations of compound, and 
the cell viability was determined by monitoring the forma 
tion of a colored formazan Salt of the tetrazolium Salt 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro 
mide (MTT) by viable cells. KeTELO1 showed no cytotoxic 
effect up to the highest concentrations tested (100 uM), 
whereas KeTELO3 (N,N'-bis(2-dimethylaminoethyl)-3,4, 
90,10-perylenetetracarboxylica acid diimide, See Example 
1) showed good cytotoxicity in a variety of human cancer 
cell lines. Thus, KeTEL01, which is a selective 
G-quadruplex interactive agent, has no acute (72 hr) cyto 
toxic effect, but the structurally analogous KeTELO3, which 
does interact with double-stranded DNA as well as 











Cytotoxicity - ICso MTT 
Cell Lines KeTELO1 KeTELO3 
MCF-7 >100 uM 18.4 uM 
BT-20 >100 uM 3.8 uM 
PC-3 >100 uM 3.8 uM 
Raji >100 uM 0.4 uM 
Example 10 
DNA Oligonucleotides 
The DNA primer extension sequence P18 (5'- 
TAATACGACTCACTATAG3) (SEQ ID No. 12) and the 
template Sequences shown in Table 1 were Synthesized using 
a PerSeptive Biosystems Expedite 8909 synthesizer and 
purified with denaturing polyacrylamide gels. The template 
DNA was diluted to 5 ng?u and dispensed into small 
aliquots. 
Example 11 
DMS Methylation Protection Assay 
The P-labeled PO74 and HT4 templates were denatured 
by heating at 90° C. for 5 min and then cooled down to room 
temperature in 50 mM Tris-HCl buffer with or without 100 
mM of K. One microliter of 1:4 ethanol-diluted DMS was 
added to 1 lug (300 ul) of annealed DNA. Aliquots were 
taken at time points as indicated in the figures, and modi 
fication reactions were stopped by adding 4 volume of stop 
buffer containing 1 M of B-mercaptoethanol and 1.5 M of 
Sodium acetate. The modification products were ethanol 
precipitated twice and treated with piperidine. After ethanol 
precipitation, the cleaved products were resolved on a 16% 
polyacrylamide gel. 
Example 12 
DNA Synthesis Arrest Assay 
This assay is a modification of that described by Weitz 
mann and co-workers (Weitzmann et al., 1996). Briefly, 
primers (P18, 24 nM) labeled with Y-P were mixed with 
template DNA (12 nM)) in a Tris-HCl buffer (10 mM Tris, 
pH 8.0) containing K" (5 mM for the PQ74 template and 50 
mM for the HT4 template) and denatured by heating at 90° 
C. for 5 min. After cooling down to room temperature, 
BSU-1051 was added at various concentrations and incu 
bated at room temperature for 15 min. The primer extension 
reactions were initiated by adding dNTP (final concentration 
100 uM), MgCl (final concentration 3 uM), and Taq DNA 
polymerase (2.5 U/reaction, Boehringer Mannheim). For 
Sequencing reactions, the TaqTrack Sequencing System 
(Promega, Madison, Wis.) was used. The Sequencing reac 
tion buffer was changed to 50 mM Tris-HCl, pH 9.0, 10 mM 
MgCl, and 50 mM K". The reactions were stopped by 
adding an equal volume of stop buffer (95% formamide, 10 
mM EDTA, 10 mM NaOH, 0.1% xylene cyanol, 0.1% 
bromphenol blue). For the temperature-dependent studies, 
the ligand concentration was fixed and the primer extension 
reactions were carried out at the temperatures indicated in 
methods. The products were separated on a 12% polyacry 
lamide Sequencing gel. The gels were then dried and Visu 
alized on a Phosphorimager (Molecular Dynamics model 
445 S1). 




The G-rich Regions of the PQ74 and HT-4 
Templates Form Intermolecular G-quadruplex 
Structures in KBuffer 
To determine the nature of the G-quadruplex Structures 
formed by the template Sequences used in this study (see 
Table 1), dimethylsulfate (DMS) was used to probe the 
accessibility of N7 of guanine in the DNA templates 
(Maxam and Gilbert, 1980). When the PQ74 template was 
methylated in 1XTE buffer, there was no apparent protection 
of any guanine N7. However, with the exception of the first 
guanine in each of the four TTGGGG (SEQ ID No. 7) 
repeats, all the guanines in the G-rich region of the PO74 
template are protected from reacting with DMS in 100 mM 
K"buffer, whereas guanines located outside the four repeats 
react strongly with DMS. This DMS protection pattern for 
the G-rich region of the PQ74 template in K'buffer suggests 
that only three guanines in each of the four TTGGGG (SEQ 
ID No. 7) repeats are involved in G-tetrad formation. This 
DMS reaction pattern is different from that observed previ 
ously by Henderson and co-workers (Henderson et al., 1990) 
with the d(TTGGGG) (SEQ ID No. 7) G-quadruplex in 
which only the first guanine of the third repeat 
(corresponding to G9 in the PQ74 template) is hypersensi 
tive to DMS methylation. On the basis of the results from the 
inventors Study, they propose a model for the G-quadruplex 
structure formed by the G-rich region of the PQ74 sequence 
consisting of d(TTGGGG) (SEQ ID No. 7). In this model, 
the first guanine of the first repeat is located in the 5' 
overhang region and is therefore open to DMS methylation. 
However, the first guanines of the Second, third, and fourth 
repeats (G5, G9, and G13, respectively) are located in the 
loop regions of the G-quadruplex. Although the N7 groups 
of these three loop guanines are not involved in hydrogen 
bonds, steric inaccessibility may protect them from DMS 
methylation. The DMS footprinting pattern shows that while 
they are partially protected from DMS methylation, this 
protection is less than that for the other guanines in the 
repeat. 
The TTAGGG (SEQ ID No. 1) repeats in the G-rich 
region of the HT-4 template also showed high DMS methy 
lation protection in K'buffer. In this particular case, all three 
guanines in each repeat were almost evenly protected from 
methylation, indicating that all of them are involved in 
G-tetrad formation. This DMS methylation pattern is con 
Sistent with the intramolecular G-quadruplex Structure pro 
posed by Patel and co-workers for the dAG (TAG) 
sequence based on NMR studies (Wang and Patel, 1993). 
(ii) BSU-1051 Binds to G-quadruplex DNA and 
Blocks DNA Synthesis in a Concentration 
Dependent Manner 
Although it has been shown that G-quadruplex Structures 
block primer extension by DNA polymerase in a 
Kaependent manner (Weitzmann et al., 1996), the inventors 
are unaware of any reports showing enhanced blockage by 
G-quadruplex -interactive agents. To determine if BSU 
1051 binding to G-quadruplex enhances the block to DNA 
Synthesis, primer extension reactions were carried out in the 
absence and presence of BSU-1051. Taq DNA polymerase 
primer eXtension on DNA templates containing four repeats 
of either TTGGGG (SEQ ID No. 7) (PQ74) or TTAGGG 











trations of BSU-1051 at 55° C. were performed. In these 
studies, K"was added at low concentrations (5 mM of K"for 
the PQ74 template and 20 mM of K for the HT4 template) 
in order to prevent overwhelming polymerase pausing due to 
formation of highly stable G-quadruplex Structures. In the 
absence of BSU-1051, there is only a slight pausing of the 
Taq DNA polymerase when it reaches the 3'-end of the 
G-rich site on the template DNA at 55 C. However, upon 
increasing the concentration of BSU-1051, enhanced paus 
ing is observed at the same site as that Seen with low 
K"concentrations. This suggests that BSU-1051 enhances 
the polymerase pausing by Stabilizing the G-quadruplex 
structure formed in the K"buffer. At high BSU-1051 
concentrations, the inventors not only observed enhanced 
pausing at the 3'-end of the G-quadrupleX site but also 
increased premature termination resulting from nonspecific 
interactions between BSU-1051 and the single-stranded 
template DNA. At a BSU-1051 concentration of 100 uM, the 
primer eXtension is completely inhibited due presumably to 
nonspecific interactions between BSU-1051 and the single 
and/or double-stranded DNA or between BSU-1051 and the 
polymerase itself. In addition to the primary pausing site at 
the beginning of the G-quadruplex site, two other Secondary 
pausing sites at the Second and third G-rich repeats are 
observed at high BSU-1051 concentrations. These pausings 
are probably induced by other structures formed by this 
G-rich Sequence. Given the fact that Secondary pausing 
beyond the first G-tetrad is not seen in the Sequencing lanes 
that contain 50 mM K", it is likely that these secondary 
pausings are caused by hairpin Structures that are Stabilized 
by BSU-1051 but not K". This suggests that BSU-1051 has 
a relatively higher affinity for G-quadruplex DNA over other 
DNA secondary structures or Single- and double-stranded 
DNA 
(iii) DNA Synthesis Arrest by the BSU-1051–G- 
quadruplex Complex Depends on the Stability of 
the G-quadruplex Structure 
To further evaluate the ability of BSU-1051 to stabilize 
G-quadruplex DNA, Taq DNA polymerase primer extension 
reactions were carried out at five different temperatures in 
the presence and absence of BSU-1051. In the absence of 
BSU-1051 polymerase pausing on the PQ74 template con 
taining four repeats of TTGGGG (SEQ ID No. 7) is almost 
lost at around 65 C., which is presumably the melting point 
of the G-quadruplex Structure formed by this G-rich region 
in the template DNA. On the other hand, in the presence of 
20 uM BSU-1051, the G-quadruplex structure is further 
Stabilized, and significant pausing is observed up to 74 C. 
In the HT4 template containing four repeats of TTAGGG 
(SEQ ID No. 1), in which the G-quadruplex structure 
formed is presumably less stable, pausing fades out at 55 C. 
in the absence of the ligand. However, in the presence of 
BSU-1051, pausing is observed up to 65 C. Thus, for both 
DNA sequences, ATm upon the addition of 20 uM BSU 
1051 is about 20° C. 
In order to confirm that the pausings Seen result from the 
formation of a G-quadruplex Structure on the template DNA, 
certain guanines in the templates were Substituted with 
7-deaza-dG. Since N7 of guanine is involved in hydrogen 
bonding in the formation of a G-quadruplex Structure, Sub 
Stitution of guanine with 7-deaza-dG should preclude the 
formation of any G-quadruplex Structure and allow for 
uninterrupted primer extension on the template by Taq DNA 
polymerase in the presence of either K'or BSU-1051. As 
shown in Table 1, two guanines in the TTAGGG (SEQ ID 
No. 1) repeat region of the HT4 template and four guanines 
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in the TTGGGG (SEQ ID No. 7) repeat region of the PQ74 
template were replaced with 7-deaza-dG. This change would 
allow the formation of no more than two intramolecular 
G-tetrads and should lead to destabilization of the intramo 
lecular G-quadruplex Structure. The primer eXtension results 
with these 7-deaza-dG substituted templates indicate that no 
Significant pausing occurs in either template in the presence 
of up to 20 mM of K'or at BSU-1051 concentrations of up 
to 50 iM. This result provides strong Support for the 
conclusion that BSU-1051 binds to and stabilizes intramo 
lecular G-quadruplex DNA, leading to pronounced DNA 




G-rich sequences such as telomeric DNA and triplet DNA 
have been reported to form parallel or antiparallel 
G-quadruplex Structures in the presence of monovalent 
cations such as Na'and K. Williamson and co-workers 
observed very Strong intramolecular UV croSS-linking for 
the sequence d(TTGGGG) (SEQ ID No. 7) in a 50 mM 
K"buffer (Williamson et al., 1989). Their results indicate 
that this sequence forms an intramolecular Structure. Using 
DMS methylation, the inventors conclude that four repeats 
of TTGGGG (SEQ ID No. 7) or TTAGGG (SEQ ID No. 1) 
within a non-G-rich Sequence are capable of forming an 
intramolecular G-quadruplex structure in K'buffer. 
Furthermore, the DMS methylation results indicate that of 
the possible types of G-quadruplex Structures that could be 
formed by d(TTGGGG) (SEQ ID No. 7), a structure 
consisting of three G-tetrads is the predominant species in 
100 mM of K'buffer. The proposed G-quadruplex structures 
formed by d(TTGGGG) (SEQ ID No. 7) and d(TTAGGG) 
(SEQ ID No. 7) repeats have diagonal loops, but alternative 
intramolecular G-quadruplex Structures formed by foldover 
hairpins consisting of three G-tetrads are also possible 
(Williamson, 1994; Wang and Patel, 1995; Wang and Patel, 
1994). However, the inventors could not differentiate 
between these two different types of intramolecular 
G-quadruplex structures by the DMS methylation pattern 
alone. 
G-rich Sequences that are capable of forming 
G-quadruplexes in vitro can be found in telomeric Sequences 
(Blackburn, 1991; Sundquist and Klug, 1989; Kang et al., 
1992), immunoglobulin Switch regions (Sen and Gilbert, 
1988), the insulin gene (Hommond-Kosacket al., 1993), the 
control region of the retinoblastoma Susceptibility gene 
(Murchie and Lilley, 1992), the promoter region of c-myc 
gene (Simonsson et al., 1998), fragile X syndrome triplet 
repeats (Nadelet al., 1995; Fry and Loeb, 1994), and HIV-1 
RNA (Awang and Sen, 1993). It has been suggested by Sen 
and Gilbert that telomeric DNA sequences may associate to 
initiate the alignment of four Sister chromatids by forming 
parallel guanine quadruplexes (Sen and Gilbert, 1990). 
Furthermore, the discovery of G-quadruplex-forming 
Sequences in the promoter region of certain genes Suggests 
that G-quadruplex Structures may play a role in the tran 
Scription regulation of these genes. Another possible role of 
G-quadruplex DNA is the regulation of telomere length, 
Since a telomeric overhang that forms a G-quadruplex 
Structure would not be a good Substrate for telomerase 
(Henderson and Blackburn, 1989; Zahler et al., 1991). The 
inventors recently have demonstrated that BSU-1051 inhib 
its primer extension by telomerase only when the Substrate 











et al., 1997). In this report, the inventors show that BSU 
1051 is able to bind to and stabilize the intramolecular 
G-quadruplex Structure formed by four telomeric repeats. 
Thus, it is reasonable to postulate that BSU-1051 inhibits 
telomerase by interacting with its Substrate (G-quadruplex 
forming telomeric repeats) rather than telomerase itself. If 
G-quadruplex Structures play important roles in other bio 
logical processes, then G-quadruplex-interactive com 
pounds Such as those described here, which Stabilize these 
Structures, may have a variety of biological effects. A Series 
of 2,6-diamidoanthraquinones, including BSU-1051, has 
been reported to moderate conventional cytotoxicity in a 
range of tumor cells (Collier and Neidle, 1988; Agbandje et 
al., 1992) and to inhibit human telomerase (Perry et al., 
1998). The G-quadruplex binding property of those com 
pounds provides a possible mechanism for their action, 
although other mechanisms involving targeting of duplex 
DNA are also likely. 
The inventors have recently proposed a model for a 
perylene-G-quadruplex complex based on NMR evidence 
(Fedoroff et al., 1998). By analogy with this structure and 
that proposed for a TMPyP-G-quadruplex structure 
(Wheelhouse et al., 1998), it seems most likely that the 
binding site of the BSU-1051 is external to the lower 
G-tetrad and within the diagonal loop (see FIG. 5). 
The block of DNA synthesis by G-quadruplex structures 
is not polymerase Specific. Woodford and co-workers 
showed that the K dependent DNA synthesis arrest by 
G-quadruplex Structures is similar for various polymerases 
(Woodword et al., 1994). The inventors have found that the 
BSU-1051-induced DNA synthesis arrest pattern is virtu 
ally identical when Taq DNA polymerase, E. coli DNA 
polymerase I (Klenow fragment), or AMV reverse tran 
scriptase is used. Given the fact that many G-rich DNA 
Sequences are capable of forming G-quadruplexes in-vitro 
(particularly Some cancer related genes and Sequences Such 
as c-myc and telomeres), G-quadruplexS are targets for 
anticancer chemotherapy. The DNA synthesis Stop assay 
described in this report provides a simple and rapid method 
for the identification of G-quadruplex-interactive agents as 
lead compounds. This polymerase Stop assay also allows an 
internal comparison for the relative binding of potential 
G-quadruplex-interactive compounds with Single and 
double-Stranded DNA targets. This is an important compari 
Son that may provide clues as to the relative cytotoxicity of 
these compounds. 
The inventors have Successfully used the present assay in 
the identification and characterization of other 
G-quadruplex-interactive compounds that are also telom 
erase inhibitors (Fedoroff et al., 1998; Wheelhouse et al., 
1998). This assay can be used to identify other 
G-quadruplex-interactive compounds with potential clinical 
utility. 
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SEQ ID NO 1 
LENGTH 6 
TYPE DNA 
ORGANISM: Artificial Sequence 
FEATURE 
Primer 
<400 SEQUENCE: 1 
ttaggg 
SEQ ID NO 2 
LENGTH 22 
TYPE DNA 
ORGANISM: Artificial Sequence 
FEATURE 
Primer 






OTHER INFORMATION: Description of Artificial Sequence: 
OTHER INFORMATION: Description of Artificial Sequence: 
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-continued 
agggittaggg ttagggittag gg 22 
<210> SEQ ID NO 3 
&2 11s LENGTH 7 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Primer 
<400 SEQUENCE: 3 
taagggit 7 
<210> SEQ ID NO 4 
&2 11s LENGTH 8 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Primer 
<400 SEQUENCE: 4 
ttagggitt 8 
<210 SEQ ID NO 5 
&2 11s LENGTH 7 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Primer 
<400 SEQUENCE: 5 
aatgggit 7 
<210> SEQ ID NO 6 
&2 11s LENGTH 7 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Primer 
<400 SEQUENCE: 6 
ttagggit 7 
<210 SEQ ID NO 7 
&2 11s LENGTH 6 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Primer 
<400 SEQUENCE: 7 
ttgggg 6 
<210 SEQ ID NO 8 
<211& LENGTH 22 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Primer 
<400 SEQUENCE: 8 
34 
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-continued 
agggittaggg ttagggittag gg 22 
<210 SEQ ID NO 9 
&2 11s LENGTH 18 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Primer 
<400 SEQUENCE: 9 
taatacgact cactatag 18 
<210> SEQ ID NO 10 
&2 11s LENGTH 80 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Primer 
<400 SEQUENCE: 10 
to caactato tatacttggg gttggggttg g g gttggggit toggggittagc ggcacgcaat 60 
tgctatagtg agtcgt atta 8O 
<210> SEQ ID NO 11 
&2 11s LENGTH 39 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Primer 
<400 SEQUENCE: 11 
catggtggitt togggittaggg ttagggittag g gttaccac 39 
<210> SEQ ID NO 12 
&2 11s LENGTH 18 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Primer 
<400 SEQUENCE: 12 
taatacgact cactatag 18 
What is claimed is: 50 increase in melting point of Said quadruplex, relative to 
1. A method of identifying a telomerase inhibitor com- unbound DNA G-quadruplex, is indicated to inhibit 
pr1SIng: telomerase activity. 
a) contacting a compound with DNA G-quadruplex; and 
b) determining the melting point of the DNA 
(3-quadruplex wherein a compound exhibiting an k . . . . 
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